SGLT2 抑制剂降低全因死亡率。
SGLT2 inhibitors reduce all-cause mortality.
机构信息
The University of Chicago, Chicago, Illinois, USA (O.F.K.).
出版信息
Ann Intern Med. 2021 May;174(5):JC52. doi: 10.7326/ACPJ202105180-052. Epub 2021 May 4.
PMID:33939484
Abstract
Silverii GA, Monami M, Mannucci E. Diabetes Obes Metab. 2021;23:1052-6. 33283969.
摘要
Silverii GA、Monami M、Mannucci E。糖尿病、肥胖与代谢。2021；23：1052-6. 33283969.
相似文献
1
SGLT2 inhibitors reduce all-cause mortality.SGLT2 抑制剂降低全因死亡率。
Ann Intern Med. 2021 May;174(5):JC52. doi: 10.7326/ACPJ202105180-052. Epub 2021 May 4.
2
In patients with type 2 diabetes or HF, SGLT2 inhibitors reduce gout-related outcomes.在 2 型糖尿病或 HF 患者中，SGLT2 抑制剂可降低痛风相关结局。
Ann Intern Med. 2023 Nov;176(11):JC125. doi: 10.7326/J23-0081. Epub 2023 Nov 7.
3
SGLT2 inhibitors increase risk for diabetic ketoacidosis in type 2 diabetes.钠-葡萄糖协同转运蛋白 2（SGLT2）抑制剂会增加 2 型糖尿病患者发生糖尿病酮症酸中毒的风险。
Ann Intern Med. 2020 Oct 20;173(8):JC40. doi: 10.7326/ACPJ202010200-040.
4
In type 2 diabetes, GLP-1 RA plus SGLT2 inhibitor vs. either drug alone reduces HbA and SBP and may reduce body weight.在 2 型糖尿病中，GLP-1RA 联合 SGLT2 抑制剂与任一药物单药治疗相比，可降低 HbA1c 和 SBP，并可能降低体重。
Ann Intern Med. 2020 Nov 17;173(10):JC52. doi: 10.7326/ACPJ202011170-052.
5
Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials.钠-葡萄糖协同转运蛋白 2 抑制剂与全因死亡率：一项随机对照试验的荟萃分析。
Diabetes Obes Metab. 2021 Apr;23(4):1052-1056. doi: 10.1111/dom.14286. Epub 2020 Dec 23.
6
Sodium-glucose co-transporter 2 inhibitors and cardiovascular outcomes: A systematic review and meta-analysis.钠-葡萄糖协同转运蛋白 2 抑制剂与心血管结局：系统评价和荟萃分析。
Eur J Prev Cardiol. 2018 Mar;25(5):495-502. doi: 10.1177/2047487318755531. Epub 2018 Jan 26.
7
Sodium-Glucose Co-Transporter 2 Inhibitors Compared with Sulfonylureas in Patients with Type 2 Diabetes Inadequately Controlled on Metformin: A Meta-Analysis of Randomized Controlled Trials.钠-葡萄糖共转运蛋白 2 抑制剂与磺脲类药物在二甲双胍控制不佳的 2 型糖尿病患者中的比较：一项随机对照试验的荟萃分析。
Clin Drug Investig. 2019 Jun;39(6):521-531. doi: 10.1007/s40261-019-00781-w.
8
Effects of antidiabetic drugs on the incidence of macrovascular complications and mortality in type 2 diabetes mellitus: a new perspective on sodium-glucose co-transporter 2 inhibitors.抗糖尿病药物对2型糖尿病大血管并发症发生率和死亡率的影响：钠-葡萄糖协同转运蛋白2抑制剂的新视角
Ann Med. 2017 Feb;49(1):51-62. doi: 10.1080/07853890.2016.1226514. Epub 2016 Sep 22.
9
Cardiovascular efficacy and safety of sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists: a systematic review and network meta-analysis.钠-葡萄糖共转运蛋白 2 抑制剂和胰高血糖素样肽-1 受体激动剂的心血管疗效和安全性：系统评价和网络荟萃分析。
Diabet Med. 2019 Apr;36(4):444-452. doi: 10.1111/dme.13898. Epub 2019 Jan 30.
10
Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis.SGLT2 抑制剂对 2 型糖尿病合并慢性肾脏病患者心血管、肾脏和安全性结局的影响：系统评价和荟萃分析。
Diabetes Obes Metab. 2019 May;21(5):1237-1250. doi: 10.1111/dom.13648. Epub 2019 Mar 4.
Zotero 插件